The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Open accessAbstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“proteome-wide mass-spectrometry demonstrated selective degradation of endogenous IKZF1/3, and ZFP91 in multiple cell lines (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide, lenalidomide and pomalidomide mediate CRL4CRBN-dependent degradation of a larger number of proteins than previously appreciated through a C2H2 ZF degron (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their recruitment to cRl4 cRBN , upon lenalidomide treatment, led to their selective ubiquitylation and proteasomal degradation, ablating their role at promoters of their target genes (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both thalidomide and lenalidomide lack specificity for iKZF2 (Krönke et al. 2014;lu et al. 2014), as it encodes a histidine in a critical thalidomidebinding position.”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies later confirmed that the efficacy of lenalidomide in 5q-MDS was actually due to the recruitment of an unexpected neo-substrate: the kinase cK1α (CSNK1A1) which resides within the long arm of chromosome 5 (5q32) (Krönke et al. 2014) (Figure 5B, i).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“lenalidomide was shown to promote the interaction between cRBN and two members of the ikaros transcription factor family: iKZF1 and iKZF3 (gandhi et al. 2014;Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“As such, lenalidomide can promote the interaction between cRl4 cRBN and both iKZF1 and iKZF3 resulting in their selective degradation which disrupts their role at gene promoters (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [10]
In the citing paper
“As described before, in the presence of IMiDs, CRBN E3 ligase induces the proteasomal degradation of a set neo-substrates, such as IKZF1/3[13,39], CK1α[40] and GSPT1[15].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [13]
In the citing paper
“This is further supported by the observations that PZ could selectively induce Bcl-xl but not Bcl-2 poly-ubiquitination and had no significant effect on the expression of the CRBN native substrate, glutamine synthetase (GS)36, and its neosubstrates recruited by thalidomide and its analogues including CK1α37, IKZF1, and IKZF3 (ref. 38) (Supplementary Fig. 1 f, g).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [38]
In the citing paper
“In brief, IMiDs bind the E3 ligase cereblon (CRBN), thus complementing a surface patch that subsequently recruits a variety of C2H2 zinc finger transcription factors for ubiquitination and degradation.48−51”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [50]
In the citing paper
“In brief, IMiDs were first shown to trigger CRBN-dependent proteasomal degradation of the C2H2-type zing-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3).[46][47][48]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“The presence of a glutamine residue in their second zing-finger domain enables IMiD-induced degradation, 47 while the histidine residues in Helios (IKZF2) do not.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“thalidomide interacts with CRBN to form a novel surface, resulting in interactions with neosubstrates such as Ikaros (IKZF1) and Aiolos (IKZF3) and their ubiquitination and subsequent proteasomal degradation.20,21”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [20]
In the citing paper
“lenalidomide and pomalidomide induce CRBN-dependent ubiquitination and degradation of Ikaros and Aiolos, transcription factors required for the development of lymphoids and survival of multiple myeloma8–10.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [8]
In the citing paper
“Molecular glues, based on the serendipitous discovery that thalidomide and its analogues act as degrader molecules, constitute another important therapeutic class1–8.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“These drugs co-opt CRBN to target IKAROS family zinc finger 1 (IKZF1) and IKZF3 for degradation3,4,24, and are now considered as pioneering examples of molecular glues.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“CRBN appears to be emerging as a preferred E3 ligase for the first wave of TPD therapeutics in clinical trials.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“Examples here include the approved IMiD class, which relies on CRBN to degrade IKZF1/IKZF3 (refs4,5) via a molecular glue mechanism”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“thalidomide and its analogues do not inhibit the enzymatic activity of CRL4CRBN, but instead confer neomorphic activity on CRBN to mediate the selective ubiquitination and resultant proteasomal degradation of the transcription factors Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 (Aiolos) in MM cells and T cells11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“In 2013, thalidomide analogues were discovered to exert their therapeutic effects by acting as a molecular glue to recruit disease-relevant neosubstrate proteins to an E3 ubiquitin ligase, resulting in neosubstrate ubiquitination and, ultimately, proteasomal degradation11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“given that proteasome inhibitors antagonize lenalidomide-induced protein degradation11,12,55.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Most known neosubstrate proteins have been identified through proteomic analyses of different cell lineages11,15,165,166.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Ebert's gourp and Kaelin Jr's group independently demonstrated that when lenalidomide binds to CRBN, a new function of CRBN is induced, namely, to ubiquitinate and degrade Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors that are known to be responsible for the maturation of B cells [25,26].”
From Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs (2016) · cites this paper as [25]
In the citing paper
“CRBN was shown to bind the drug thalidomide in its substrate binding pocket, thereby creating a new surface to recruit other proteins for ubiquitination and degradation, such as the transcription factors Ikaros and Aiolos (IKZF1 and 3, respectively) or the kinase CK1α [70–72].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [72]
In the citing paper
“The clinical efficacy of IMiDs is driven at least in part by their capacity to induce CRBN-mediated degradation of neo-substrates: cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
In the citing paper
“cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan‐Smith, E., Dalton, J., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,777
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191
The ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)
Ong, S., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.427 · Cited by 917
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,006
Shirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108532 · Cited by 123
Self-citationMolecular mechanisms of thalidomide and its derivatives
Ito, T., & Handa, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.016 · Cited by 123
Ctortecka, C., Clark, N. M., Boyle, B. W., Seth, A., Mani, D. R., Udeshi, N. D., & Carr, S. A. (2024) · Nature Communications · doi:10.1038/s41467-024-49651-w · Cited by 123
Self-citationMayor-Ruiz, C., Jaeger, M. G., Bauer, S., Brand, M., Sin, C., Hanzl, A., Mueller, A. C., Menche, J., & Winter, G. E. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.013 · Cited by 119
Strategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 120
Bellinger, A. M., Arteaga, C. L., Force, T. L., Humphreys, B. D., Demetri, G. D., Druker, B. J., & Moslehi, J. J. (2015) · Circulation · doi:10.1161/circulationaha.115.010484 · Cited by 119
A bibliometric analysis of PROTAC from 2001 to 2021
Li, D., Yu, D., Li, Y., & Yang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114838 · Cited by 125
Byrd, J. C., Jones, J. J., Woyach, J. A., Johnson, A. J., & Flynn, J. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.8262 · Cited by 117
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 122
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
Ng, S. Y., Yoshida, N., Christie, A. L., Ghandi, M., Dharia, N. V., Dempster, J. M., Murakami, M. A., Shigemori, K., Morrow, S. N., Scoyk, A. V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04356-9 · Cited by 112
Pyrazinamide triggers degradation of its target aspartate decarboxylase
Gopal, P., Sarathy, J. P., Yee, M., Ragunathan, P., Shin, J. S., Bhushan, S., Zhu, J., Akopian, T. N., Kandror, O., Lim, T. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15516-1 · Cited by 118
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma
Seong, B. K. A., Dharia, N. V., Lin, S., Donovan, K. A., Chong, S., Robichaud, A. L., Conway, A. S., Hamze, A., Ross, L. S., Alexe, G., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.003 · Cited by 118
Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
Self-citationRamakrishnan, G., Matta, H., Tolani, B., Triche, T. J., & Chaudhary, P. M. (2015) · Oncogene · doi:10.1038/onc.2015.245 · Cited by 114
Jacques, V., Czarnik, A. W., Judge, T. M., der Ploeg, L. H. T. V., & DeWitt, S. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417832112 · Cited by 112
Rapid and deep-scale ubiquitylation profiling for biology and translational research
Udeshi, N. D., Mani, D. R., Satpathy, S., Fereshetian, S., Gasser, J. A., Svinkina, T., Olive, M. E., Ebert, B. L., Mertins, P., & Carr, S. A. (2020) · Nature Communications · doi:10.1038/s41467-019-14175-1 · Cited by 110
Self-citationProtein Degradation and the Pathologic Basis of Disease
Hanna, J. W., Guerra-Moreno, Á., Ang, J., & Micoogullari, Y. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.09.004 · Cited by 115
Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders
Lu, P., Cheng, Y., Xue, L., Ren, X., Xu, X., Chen, C., Cao, L., Li, J., Wu, Q., Sun, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.015 · Cited by 119
Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Fowler, N. H., Cheah, C. Y., Gascoyne, R. D., Gribben, J. G., Neelapu, S. S., Ghia, P., Bollard, C. M., Ansell, S., Curran, M. A., Wilson, W. H., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139493 · Cited by 118
Glucocorticoids in multiple myeloma: past, present, and future
Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 113
Myers, S. A., Rhoads, A., Cocco, A. R., Peckner, R., Haber, A. L., Schweitzer, L. D., Krug, K., Mani, D. R., Clauser, K. R., Rozenblatt–Rosen, O., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001259 · Cited by 105
Self-citationAcetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma
Li, Z., Liu, H., He, J., Wang, Z., Yin, Z., You, G., Wang, Z., Davis, R. E., Lin, P., Bergsagel, P. L., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.011 · Cited by 110
Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex
Matyskiela, M. E., Clayton, T., Zheng, X., Mayne, C., Tran, E., Carpenter, A., Pagarigan, B., McDonald, J., Rolfe, M., Hamann, L. G., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0405-9 · Cited by 103
Design and synthesis of selective degraders of EGFRL858R/T790M mutant
Zhang, X., Xu, F., Tong, L., Zhang, T., Xie, H., Lu, X., Ren, X., & Ding, K. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112199 · Cited by 110
Targeting the undruggables—the power of protein degraders
Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 112
Toumishey, E., Prasad, A., Dueck, G., Chua, N. S., Finch, D. L., Johnston, J. B., van der Jagt, R., Stewart, D., White, D. J., Belch, A. R., et al. (2014) · Cancer · doi:10.1002/cncr.29103 · Cited by 105
Phthalimide conjugations for the degradation of oncogenic PI3K
Li, W., Gao, C., Zhao, L., Yuan, Z., Chen, Y., & Jiang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.066 · Cited by 105
Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies
Lettre, G., & Bauer, D. E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01341-0 · Cited by 104
Cereblon modulators: Low molecular weight inducers of protein degradation
Chamberlain, P. P., & Cathers, B. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.004 · Cited by 106
Zhu, Y. X., Shi, C.-X., Bruins, L. A., Wang, X., Riggs, D. L., Porter, B., Ahmann, J. M., de Campos, C. B., Braggio, E., Bergsagel, P. L., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0173-0 · Cited by 105
Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia
Garnar-Wortzel, L., Bishop, T. R., Kitamura, S., Milosevich, N., Asiaban, J. N., Zhang, X., Zheng, Q., Chen, E., Ramos, A. R., Ackerman, C. J., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01550 · Cited by 98
Nishiguchi, G., Keramatnia, F., Min, J., Chang, Y., Jonchère, B., Das, S., Actis, M., Price, J. E., Chepyala, D., Young, B. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01313 · Cited by 104
Gao, J., Mfuh, A., Amako, Y., & Woo, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11639 · Cited by 102
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies
Li, W., Garcia, D. A., Cornell, R. F., Gailani, D., Laubach, J. P., Maglio, M. E., Richardson, P. G. G., & Moslehi, J. J. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3350 · Cited by 103
Dulmovits, B. M., Appiah‐Kubi, A., Papoin, J., Hale, J., He, M., Al‐Abed, Y., Didier, S., Gould, M., Husain-Krautter, S., Singh, S. A., et al. (2015) · Blood · doi:10.1182/blood-2015-09-667923 · Cited by 102
PROTAC-mediated crosstalk between E3 ligases
Steinebach, C., Kehm, H., Lindner, S., Vu, L. P., Köpff, S., Mármol, Á. L., Weiler, C., Wagner, K. G., Reichenzeller, M., Krönke, J., et al. (2019) · Chemical Communications · doi:10.1039/c8cc09541h · Cited by 101
Self-citationLonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00290-3 · Cited by 101
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
Richardson, P. G. G., Trudel, S., Popat, R., Mateos, M., Vangsted, A. J., Ramasamy, K., Martínez‐López, J., Quach, H., Orlowski, R. Z., Arnao, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303194 · Cited by 102
DCAF16-Based Covalent Handle for the Rational Design of Monovalent Degraders
Lim, M., Cong, T. D., Orr, L. M., Toriki, E. S., Kile, A. C., Papatzimas, J. W., Lee, E., Lin, Y., & Nomura, D. K. (2024) · ACS Central Science · doi:10.1021/acscentsci.4c00286 · Cited by 106
IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation
Park, S.-M., Cho, H., Thornton, A. M., Barlowe, T. S., Chou, T., Chhangawala, S., Fairchild, L., Taggart, J., Chow, A., Schurer, A., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.016 · Cited by 97
A covalently bound inhibitor triggers EZH2 degradation through CHIP‐mediated ubiquitination
Wang, X., Cao, W., Zhang, J., Yan, M., Xu, Q., Wu, X., Wan, L., Zhang, Z., Zhang, C., Qin, X., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201694058 · Cited by 100
Lin, X., Xiang, H., & Luo, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112689 · Cited by 104
Target protein localization and its impact on PROTAC-mediated degradation
Simpson, L. M., Glennie, L., Brewer, A., Zhao, J., Crooks, J., Shpiro, N., & Sapkota, G. P. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.004 · Cited by 106
Dixon, T. J., MacPherson, D. J., Mostofian, B., Dauzhenka, T. A., Lotz, S., McGee, T. D., Shechter, S., Shrestha, U. R., Wiewiora, R., McDargh, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33575-4 · Cited by 114
Pech, M. F., Fong, L. E., Villalta, J. E., Chan, L. J., Kharbanda, S., O’Brien, J. J., McAllister, F. E., Firestone, A. J., Jan, C. H., & Settleman, J. E. (2019) · eLife · doi:10.7554/elife.47362 · Cited by 98
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
Otáhal, P., Průková, D., Král, V., Fábry, M., Vočková, P., Latečková, L., Trněný, M., & Klener, P. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115940 · Cited by 98
Epigenetic regulation of fetal globin gene expression in adult erythroid cells
Ginder, G. D. (2014) · Translational research · doi:10.1016/j.trsl.2014.05.002 · Cited by 97
A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction
Ting, P. Y., Borikar, S., Kerrigan, J. R., Thomsen, N. M., Aghania, E., Hinman, A. E., Reyes, A., Pizzato, N., Fodor, B. D., Wu, F., et al. (2024) · Science · doi:10.1126/science.adk6129 · Cited by 97
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
Self-citationJin, Y., Chen, K., Paepe, A. D., Hellqvist, E., Krstic, A. D., Metang, L. A., Gustafsson, C., Davis, R. E., Levy, Y. M., Surapaneni, R., et al. (2018) · Blood · doi:10.1182/blood-2017-09-808063 · Cited by 96
Ahn, G., Banik, S. M., & Bertozzi, C. R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.024 · Cited by 98
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition
Petzold, G., Gainza, P., Annunziato, S., Lamberto, I., Trenh, P., McAllister, L. A., DeMarco, B., Schwander, L., Bunker, R. D., Zlotosch, M., et al. (2025) · Science · doi:10.1126/science.adt6736 · Cited by 117
Lenalidomide induces degradation of IKZF1 and IKZF3
Krönke, J., Hurst, S. N., & Ebert, B. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.941742 · Cited by 94
Self-citationAbruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Vulpis, E., Borrelli, C., Zitti, B., Petrucci, M. T., Ricciardi, M. R., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0362-2 · Cited by 97
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95
CRL4ACRBN E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis
Liu, J., Ye, J., Zou, X., Xu, Z., Feng, Y., Zou, X., Chen, Z., Li, Y., & Cang, Y. (2014) · Nature Communications · doi:10.1038/ncomms4924 · Cited by 92
Protein degradation technology: a strategic paradigm shift in drug discovery
Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X., & Qin, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01146-7 · Cited by 96
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 96
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 90
Mazzurana, L., Forkel, M., Rao, A., Acker, A. V., Kokkinou, E., Ichiya, T., Almer, S. H., Höög, C., Friberg, D., & Mjösberg, J. (2019) · European Journal of Immunology · doi:10.1002/eji.201848075 · Cited by 91
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Vo, J. N., Wu, Y., Mishler, J., Hall, S., Mannan, R., Wang, L., Yu, N., Zhou, J. R., Hopkins, A. C., Estill, J. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31430-0 · Cited by 103
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
Fedele, P. L., Willis, S. N., Liao, Y., Low, M. S. Y., Rautela, J., Segal, D., Gong, J., Huntington, N. D., Shi, W., Huang, D. C. S., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850727 · Cited by 94
An overview of kinase downregulators and recent advances in discovery approaches
Wang, B., Wu, H., Hu, C., Wang, H., Liu, J., Wang, W., & Liu, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00826-7 · Cited by 93
Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
Furihata, H., Yamanaka, S., Honda, T., Miyauchi, Y., Asano, A., Shibata, N., Tanokura, M., Sawasaki, T., & Miyakawa, T. (2020) · Nature Communications · doi:10.1038/s41467-020-18488-4 · Cited by 89
Fionda, C., Abruzzese, M. P., Zingoni, A., Cecere, F., Vulpis, E., Peruzzi, G., Soriani, A., Molfetta, R., Paolini, R., Ricciardi, M. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4603 · Cited by 91
Yamanaka, S., Murai, H., Saito, D., Abe, G., Tokunaga, E., Iwasaki, T., Takahashi, H., Takeda, H., Suzuki, T., Shibata, N., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105375 · Cited by 89
Cancer Evolution: A Multifaceted Affair
Ciriello, G., Magnani, L., Aitken, S. J., Akkari, L., Behjati, S., Hanahan, D., Landau, D. A., López-Bigas, N., Lupiáñez, D. G., Marine, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0530 · Cited by 91
Regulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin Ligases
Vittal, V., Stewart, M. D., Brzović, P. S., & Klevit, R. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.675165 · Cited by 88
Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library
Powell, C. E., Du, G., Che, J., He, Z., Donovan, K. A., Yue, H., Wang, E. S., Nowak, R. P., Zhang, T., Fischer, E. S., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00520 · Cited by 87
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation
Sun, D., Zhang, J., Dong, G., He, S., & Sheng, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01159 · Cited by 89
Ocio, E. M., Fernández‐Lázaro, D., San‐Segundo, L., López‐Corral, L., Corchete, L. A., Gutierrez, N. C., Garayoa, M., Paíno, T., García-Gómez, A., Delgado, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.238 · Cited by 91
A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders
Millrine, D., & Kishimoto, T. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.02.006 · Cited by 88
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.04.028 · Cited by 89
Dimopoulos, K., Helbo, A. S., Munch‐Petersen, H. F., Sjø, L. D., Christensen, J. F., Kristensen, L. S., Asmar, F., Hermansen, E., O'Connel, C., Gimsing, P., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12157 · Cited by 89
Fecteau, J.-F., Corral, L. G., Ghia, E. M., Gaidarova, S., Futalan, D., Bharati, I. S., Cathers, B. E., Schwaederle, M. C., Cui, B., Lopez‐Girona, A., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559591 · Cited by 86
Promising therapies in multiple myeloma
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood · doi:10.1182/blood-2015-03-575365 · Cited by 86
Yamanaka, S., Horiuchi, Y., Matsuoka, S., Kido, K., Nishino, K., Maeno, M., Shibata, N., Kosako, H., & Sawasaki, T. (2022) · Nature Communications · doi:10.1038/s41467-021-27818-z · Cited by 84
p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates
Nguyen, T. V., Li, J., Lu, C.-C. (., Mamrosh, J. L., Lu, G., Cathers, B. E., & Deshaies, R. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700949114 · Cited by 85
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis
Wang, S., Juan, J., Zhang, Z., Du, Y., Xu, Y., Tong, J., Cao, B., Moran, M. F., Zeng, Y., & Mao, X. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.450 · Cited by 85
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 89
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies
Bianchi, G., Zhang, Y., & Comenzo, R. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.003 · Cited by 83
Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy
Spano, D., & Catara, G. (2023) · Cells · doi:10.3390/cells13010029 · Cited by 86
Superenhancer reprogramming drives a B-cell–epithelial transition and high-risk leukemiaPreprint
Hu, Y., Zhang, Z., Kashiwagi, M., Yoshida, T., Joshi, I., Jena, N., Somasundaram, R., Emmanuel, A. O., Sigvardsson, M., Fitamant, J., et al. (2016) · Genes & Development · doi:10.1101/gad.283762.116 · Cited by 86
Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83
Fang, J., Liu, X., Bolanos, L., Barker, B., Rigolino, C., Cortelezzi, A., Oliva, E. N., Cuzzola, M., Grimes, H. L., Fontanillo, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4127 · Cited by 83
Thalidomide mimics uridine binding to an aromatic cage in cereblon
Hartmann, M. D., Boichenko, I., Coles, M., Zanini, F., Lupas, A. N., & Hernandez Alvarez, B. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.10.010 · Cited by 83
DNA-encoded library-enabled discovery of proximity-inducing small molecules
Mason, J. W., Chow, Y. T., Hudson, L., Tutter, A., Michaud, G., Westphal, M. V., Shu, W., Ma, X., Tan, Z. Y., Coley, C. W., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01458-4 · Cited by 83
Self-citationContinuous evolution of compact protein degradation tags regulated by selective molecular glues
Mercer, J. A. M., DeCarlo, S. J., Burman, S. S. R., Sreekanth, V., Nelson, A. T., Hunkeler, M., Chen, P. J., Donovan, K. A., Kokkonda, P., Tiwari, P. K., et al. (2024) · Science · doi:10.1126/science.adk4422 · Cited by 85
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Pisa, R., & Kapoor, T. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0596-8 · Cited by 84
Paiva, B., Mateos, M., Sánchez‐Abarca, L. I., Puig, N., Vídriales, M., López‐Corral, L., Corchete, L. A., Hernández, M., Bargay, J., de Arriba, F., et al. (2015) · Blood · doi:10.1182/blood-2015-10-662320 · Cited by 82
Viswanathan, S. R., Nogueira, M. F., Buss, C. G., Krill-Burger, J. M., Wawer, M. J., Małolepsza, E., Berger, A. C., Choi, P. S., Shih, J., Taylor, A. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0155-3 · Cited by 80
Self-citationHumanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs
Gemechu, Y., Millrine, D., Hashimoto, S., Prakash, J., Sanchenkova, K., Metwally, H., Parajuli, G., Kang, S., & Kishimoto, T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814446115 · Cited by 78
Using Ubiquitin Binders to Decipher the Ubiquitin Code
Mattern, M. R., Sutherland, J. D., Kadimisetty, K., Barrio, R., & Rodríguez, M. S. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.01.011 · Cited by 80
Targeting chromatin complexes in fusion protein-driven malignancies
Brien, G. L., Stegmaier, K., & Armstrong, S. A. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0132-x · Cited by 84
ZNF410 represses fetal globin by singular control of CHD4
Vinjamur, D. S., Yao, Q., Cole, M. A., McGuckin, C., Ren, C., Zeng, J., Hossain, M. A., Luk, K., Wolfe, S. A., Pinello, L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00843-w · Cited by 83
Rui, H., Ashton, K. S., Min, J., Wang, C. W., & Potts, P. R. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00207h · Cited by 87
Metadata
- Authors
- Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S. L., Carr, S. A., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 301-305
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4077049
- OpenAlex
- W2015345028
- Semantic Scholar
- bf4fc60d821257f664ef758f219b75586ad0adaa
- Cited by
- 1,879
- References
- 31
- Citations by year
- 2026: 159 · 2025: 188 · 2024: 185 · 2023: 169 · 2022: 176 · 2021: 196 · 2020: 186 · 2019: 138 · 2018: 125 · 2017: 100 · 2016: 102 · 2015: 88 · 2014: 59
- FWCI
- 37.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5p01ca078378-15)
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Human Genome Research Institute (RL1HG004671)
- National Cancer Institute (P01-CA078378, P50CA100707, P01CA108631, P01CA155258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, multiple myeloma, IKZF1, IKZF3, selective protein degradation, E3 ubiquitin ligase, ubiquitination, mechanism of action, IL-2 production, T cells, transcription factors
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Interleukin-2, Multiple Myeloma, T-Lymphocytes, Thalidomide, Cell Line, Tumor, Ikaros Transcription Factor, Ubiquitination, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
